Category Research

Thermo Fisher

Thermo Fisher Scientific Unveils Integrated Platform to Streamline and Accelerate Biologics Development

Thermo Fisher Scientific Introduces Unified Platform to Speed Biologics Development Thermo Fisher Scientific Inc., a global leader in scientific services and life sciences solutions, has introduced a next-generation, integrated cell line development (CLD) platform designed to accelerate biologics development timelines…

Read MoreThermo Fisher Scientific Unveils Integrated Platform to Streamline and Accelerate Biologics Development

Alto Neuroscience Announces Topline Phase 2 Proof-of-Concept Results for ALTO-101 and Showcases Pipeline Progress

Alto Neuroscience Shares Topline Results from Phase 2 Proof-of-Concept Trial of ALTO-101 and Highlights Ongoing Pipeline Progress Alto Neuroscience, Inc. has announced topline results from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment…

Read MoreAlto Neuroscience Announces Topline Phase 2 Proof-of-Concept Results for ALTO-101 and Showcases Pipeline Progress

LumaCyte’s Analytical Method Recognized in Newly Released ISO Global Standard for Viral Vector Quantification

LumaCyte’s Analytical Method Recognized in Newly Issued ISO Global Standard for Viral Vector Quantification LumaCyte has announced a significant milestone for its proprietary analytical technology, revealing that its approach has been formally incorporated into the newly published global standard for…

Read MoreLumaCyte’s Analytical Method Recognized in Newly Released ISO Global Standard for Viral Vector Quantification

Parse Biosciences, a QIAGEN Company, Introduces FFPE-Compatible Barcoding Technology for Whole Transcriptome Single-Cell Analysis

Introduces FFPE-Compatible Barcoding Innovation Enabling Whole Transcriptome Single-Cell Analysis Parse Biosciences, a subsidiary of QIAGEN and a recognized leader in scalable single-cell sequencing technologies, has announced the commercial launch and immediate availability of its Evercode™ Whole Transcriptome FFPE kits. This…

Read MoreParse Biosciences, a QIAGEN Company, Introduces FFPE-Compatible Barcoding Technology for Whole Transcriptome Single-Cell Analysis

Meiji Seika Pharma Backs Centivax to Advance Next-Generation Universal Vaccine Platform

Meiji Seika Pharma Invests in Centivax to Advance Universal Vaccine Innovation and Broaden Global Infectious Disease Preparedness Meiji Seika Pharma Co., Ltd., a leading Japanese pharmaceutical company with a long-standing commitment to advancing public health, has announced a strategic investment…

Read MoreMeiji Seika Pharma Backs Centivax to Advance Next-Generation Universal Vaccine Platform

PepGen Reports Phase 2 FREEDOM2 Low-Dose Cohort Results Showing Strong Safety and Efficacy Signals

PepGen Reports Encouraging Phase 2 Data for PGN-EDODM1 in Myotonic Dystrophy Type 1, Advances Higher-Dose Cohort in FREEDOM2 Trial PepGen Inc., a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapeutics, has announced new clinical data from the 5 mg/kg…

Read MorePepGen Reports Phase 2 FREEDOM2 Low-Dose Cohort Results Showing Strong Safety and Efficacy Signals
Roche

Roche Introduces cobas MPX-E Assay, a 4-in-1 Donor Screening Test to Enhance Global Blood Safety

Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro diagnostic test designed to detect and differentiate multiple high-risk viral…

Read MoreRoche Introduces cobas MPX-E Assay, a 4-in-1 Donor Screening Test to Enhance Global Blood Safety

Novartis to Acquire Excellergy, Inc., Strengthening Allergy Leadership with Next-Generation Anti-IgE Innovation

Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on the development of next-generation therapies targeting immunoglobulin E (IgE)-driven diseases.…

Read MoreNovartis to Acquire Excellergy, Inc., Strengthening Allergy Leadership with Next-Generation Anti-IgE Innovation

Nordic Cold Chain Solutions Unveils GLP-1 and Small-Format Packaging Innovation Lab

Nordic Cold Chain Solutions Unveils Innovation Lab Focused on GLP-1 and Small-Format Packaging Solutions Nordic Cold Chain Solutions has announced the launch of its GLP-1 & Small-Format Packaging Innovation Lab, a new customer-focused initiative aimed at addressing the growing logistical…

Read MoreNordic Cold Chain Solutions Unveils GLP-1 and Small-Format Packaging Innovation Lab

Bio-Techne Expands COMET™ Suite with Modular Innovations to Advance Spatial Biology

Bio-Techne Expands Spatial Biology Capabilities with Modular Enhancement of the COMET™ Suite Bio-Techne Corporation has announced a significant expansion of its spatial biology capabilities with the introduction of new tools within its COMET™ technology platform. The launch of SPYRE™ Focus…

Read MoreBio-Techne Expands COMET™ Suite with Modular Innovations to Advance Spatial Biology

Seaport Therapeutics Highlights GlyphAllo™ (SPT-300) Study in Science Translational Medicine

Seaport Therapeutics, Founded by PureTech, Reports Science Translational Medicine Publication Highlighting GlyphAllo™ (SPT-300) as a First-in-Class Triglyceride-Mimetic Prodrug Achieving Therapeutic Drug Levels in Humans PureTech Health plc has highlighted a significant scientific milestone achieved by its Founded Entity, Seaport Therapeutics,…

Read MoreSeaport Therapeutics Highlights GlyphAllo™ (SPT-300) Study in Science Translational Medicine